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SCIENTIFIC EDITORIAL
Pretreatment  with  P2Y12 inhibitors  in
non—ST-segment  elevation  acute  coronary
syndrome:  Time  to  revise  the  guidelines?
Pré-traitement  des  syndromes  coronaires  aigus  sans  sus-décalage
du  segment  ST  avec  les  inhibiteurs  de  P2Y12 :  l’heure  de  changer
les  recommandations  ?
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Antiplatelet  agents  remain  a cornerstone  of  treatment  for  acute  coronary  syndrome.  More
than  15  years  after  the  introduction  of  ticlopidine  in  coronary  artery  disease,  the  com-
bination  of  aspirin  with  P2Y12 inhibitors  has  became  a  standard  of  care.  However,  the
optimal  timing  of  the  introduction  of  P2Y12 inhibitors  remains  controversial.  Clopidogrel
is  a  prodrug  that  needs  hepatic  biotransformation  in  two  important  steps  to  irreversibly
block  the  P212 receptor.  New  P2Y12 inhibitors  —  namely,  prasugrel  and  ticagrelor  —  have
a  simpler  hepatic  metabolization  and  induce  a  rapid  and  intense  level  of  platelet  inhibi-
tion  [1,2].  These  agents  are  proposed  as  ﬁrst-line  treatment  for  non—ST-segment  elevation
acute  coronary  syndromes  (NSTE-ACS);  however,  the  question  of  timing  of  administration
has  never  been  addressed  [3,4]  in  a  dedicated  randomized  study.  European  and  Ameri-
can  guidelines  [5,6]  recommend  giving  P2Y12 inhibitors  as  soon  as  possible;  however,  thePrasugrel  ;
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evidence  to  support  this  statement  is  weak.  A  recent  meta-analysis  [7]  did  not  show  a
survival  beneﬁt  for  clopidogrel  pretreatment  in  37,000  patients  undergoing  percutaneous
coronary  intervention  (PCI),  while  there  was  an  excess  of  major  bleeding  and  little  impact
on  ischemic  outcomes.
Abbreviations: CABG, coronary artery bypass graft; NSTE-ACS, non—ST-segment elevation acute coronary syndrome; NSTEMI, non—ST-
segment elevation myocardial infarction; PCI, percutaneous coronary intervention.
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Roche,  Royal  College  Physicians,  Sanoﬁ-Aventis,  Stentys,igure 1. Primary efﬁcacy and safety endpoints at 30 days in the
otal and percutaneous coronary intervention (PCI) populations.
IMI: Thrombolysis in Myocardial Infarction Study Group.
The  ACCOAST  study  [8]  has  addressed  the  question  of
ptimal  timing  of  P2Y12 inhibition  in  patients  with  non—ST-
egment  elevation  myocardial  infarction  (NSTEMI)  managed
nvasively  within  48  hours  of  admission.  In  this  study,  4033
atients  were  randomized  to  receive  prasugrel  as  pretreat-
ent  or  to  selectively  receive  prasugrel  at  the  time  of  PCI.
espite  effective  platelet  inhibition  at  the  time  of  PCI,  pre-
reatment  with  prasugrel  did  not  reduce  the  occurrence
f  the  primary  endpoint  (a  composite  of  cardiovascular
eath,  myocardial  infarction,  stroke,  urgent  revasculari-
ation  or  glycoprotein  IIb/IIIa  inhibitor  rescue  therapy)
Fig.  1).  Moreover,  pretreatment  was  associated  with  a
wofold  increase  in  major  bleeding  complications  at  7  days.
nterestingly,  among  the  69%  of  patients  who  underwent
CI,  no  evidence  of  reduction  in  ischemic  complications  was
bserved  and  pretreatment  was  associated  with  a three-
old  increased  risk  of  major  bleeding  complications.  Finally,
here  were  signiﬁcantly  more  major  and  life-threatening
leeding  complications  not  related  to  coronary  artery  bypass
raft  (CABG)  surgery  in  the  pretreatment  group  than  in  the
ontrol  group.  These  results  were  consistent  across  all  the
ubgroups,  including  in  patients  in  whom  radial  access  was
sed  for  PCI.
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The  results  of  the  ACCOAST  study  offer  new  insights  into
retreatment  with  P2Y12 inhibitors  in  NSTEMI.  The  use  of
ew  P2Y12 inhibitors  in  NSTE-ACS  may  be  postponed  to  the
ime  of  the  decision  about  PCI,  to  avoid  overtreatment  in
atients  who  may  need  CABG  surgery  or  medical  treatment
9].  Can  the  ACCOAST  results  be  applied  to  other  P2Y12
nhibitors,  such  as  clopidogrel  and  ticagrelor?  For  clopid-
grel,  the  oldest  studies  suggest  a  potential  beneﬁt  for
retreatment  when  there  is  a  very  long  delay  between  ran-
omization  and  PCI  [10,11].  More  recent  studies  have  not
onﬁrmed  the  beneﬁt  of  pretreatment  with  shorter  delays
nd  higher  doses  of  clopidogrel  [12,13].  For  ticagrelor,  in
he  PLATO  trial  [4],  all  patients  were  pretreated  with  clo-
idogrel,  ticagrelor  or  both  before  PCI;  the  question  of
retreatment  has  not  been  addressed  for  ticagrelor.
The  potential  risk/beneﬁt  ratio  for  pretreatment  with
ew  P2Y12 inhibitors  must  now  be  reconsidered  for  these
gents  in  NSTE-ACS.  Practical  implications  may  be  as  fol-
ows:  in  patients  with  a  short  delay  (<  24—48  hours)  from
dmission  to  angiography,  pretreatment  should  be  avoided;
n  patients  with  a  delay  from  admission  to  angiography
f  >  48  hours,  pretreatment  with  either  clopidogrel  (on  the
asis  of  old  data)  or  ticagrelor  (without  data)  may  be  con-
idered.
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